MCB Clinical Research Centers LLC

1. Otsuka Pharmaceutical Development & Commercialization, Inc. $1,261,129 19 payments
2. Genentech, Inc. $714,978 46 payments
3. Sage Therapeutics, Inc. $432,150 47 payments
4. Allergan Inc. $195,256 58 payments
5. Supernus Pharmaceuticals, Inc. $174,858 31 payments
6. Alkermes, Inc. $87,230 25 payments
7. ACADIA Pharmaceuticals Inc $72,959 19 payments
8. Janssen Research & Development, LLC $71,772 8 payments
9. Sunovion Pharmaceuticals Inc. $63,893 14 payments
10. ITI, Inc. $40,207 12 payments

1. Phase III Study of Balovaptan in Adults With Asd $673,512 38 payments
2. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole As Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder. $580,102 5 payments
3. A Multi-Center, Randomized, Controlled Trial to Evaluate the Effectiveness of A Digital Therapeutic (CT-152) As Adjunctive Therapy in Adult Subjects Diagnosed With Major Depressive Disorder $193,195 3 payments
4. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment With Sage-217 in Adult Subjects With Major Depressive Disorder $188,424 30 payments
5. A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder $167,140 2 payments
6. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment with SAGE-217 in Adult Subjects with Major Depressive Disorder $129,889 2 payments
7. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-5138 in Adults With Treatment Resistant Depression $109,227 13 payments
8. A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder (Trial 405-201-00013) $100,212 1 payment
9. A Comparative Study of Sage-217 Plus Sertraline Versus Placebo Plus Sertraline in Adults With Major Depressive Disorder $75,399 12 payments
10. A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficithyperactivity Disorder Trial 405-201-00013 $74,132 1 payment

1. Patient care $70,220 8 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.